Disclosures: Andrea Mospan: Nothing to Disclose, Breda Munoz: Nothing to Disclose, Heather Morris: Nothing to Disclose, Aarth Sheth: Nothing to Disclose, Rakesh Luthra: Nothing to Disclose 1080 VALIDATION AND EPIDEMIOLOGIC DEFINITION OF THE NOVEL STEATOTIC LIVER DISEASE NOMENCLATURE IN A NATIONAL COHORT WITH CIRRHOSIS Catherine Mezzacappa 1 Pedro Ochoa-Allemant 2 Marina Serper 3 Tamar Taddei 1 Binu John 4 David Kaplan 2 Nadim Mahmud 5 , 1 Yale University, 2 University of Pennsylvania, 3 University of Pennsylvania Health System, 4 University of Miami, 5 Hospital of the University of Pennsylvania Background: Novel steatotic liver disease (SLD) definitions were introduced in 2023 with a diagnostic algorithm based on the presence of cardiometabolic risk factors (CMRFs) and thresholds for alcohol exposure to define metabolic dysfunction-associated SLD (MASLD), alcohol-associated liver disease (ALD), and metabolic and alcohol-associated liver disease (MetALD)
Stem cell injections are safe, with minimal risks or side effects, and are well-tolerated by most patients
Research suggests that TMDC-based neuromorphic devices can help reduce oxidative stress and neuroinflammation, two major contributors to neurodegenerative diseases
(Your dermatologist may distinguish this with the use of imaging or by examination)
